AIMS: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolized by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a potent and selective sEH inhibitor that was tested in two phase I studies. METHODS: Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers. Once daily doses of 6 or 18 mg or placebo were administered for 14 days to obese smokers. Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food. Data on safety, pharmacokinetics and biliary metabolites were collected. RESULTS: GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug. The most frequent AEs were headache and contact dermatitis. Plasma concentrations of GSK2256294 increased with single doses, with a half-life averaging 25-43 h. There was no significant effect of age, food or gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 h. There were no significant changes in serum VEGF or plasma fibrinogen. CONCLUSIONS: GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity. These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.
AIMS: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolized by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a potent and selective sEH inhibitor that was tested in two phase I studies. METHODS: Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers. Once daily doses of 6 or 18 mg or placebo were administered for 14 days to obese smokers. Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food. Data on safety, pharmacokinetics and biliary metabolites were collected. RESULTS: GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug. The most frequent AEs were headache and contact dermatitis. Plasma concentrations of GSK2256294 increased with single doses, with a half-life averaging 25-43 h. There was no significant effect of age, food or gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 h. There were no significant changes in serum VEGF or plasma fibrinogen. CONCLUSIONS: GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity. These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.
Authors: Y Kasahara; R M Tuder; L Taraseviciene-Stewart; T D Le Cras; S Abman; P K Hirth; J Waltenberger; N F Voelkel Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: Dipak Panigrahy; Matthew L Edin; Craig R Lee; Sui Huang; Diane R Bielenberg; Catherine E Butterfield; Carmen M Barnés; Akiko Mammoto; Tadanori Mammoto; Ayala Luria; Ofra Benny; Deviney M Chaponis; Andrew C Dudley; Emily R Greene; Jo-Anne Vergilio; Giorgio Pietramaggiori; Sandra S Scherer-Pietramaggiori; Sarah M Short; Meetu Seth; Fred B Lih; Kenneth B Tomer; Jun Yang; Reto A Schwendener; Bruce D Hammock; John R Falck; Vijaya L Manthati; Donald E Ingber; Arja Kaipainen; Patricia A D'Amore; Mark W Kieran; Darryl C Zeldin Journal: J Clin Invest Date: 2011-12-19 Impact factor: 14.808
Authors: Jun Yang; Jennifer Bratt; Lisa Franzi; Jun-Yan Liu; Guodong Zhang; Amir A Zeki; Christoph F A Vogel; Keisha Williams; Hua Dong; Yanping Lin; Sung Hee Hwang; Nicholas J Kenyon; Bruce D Hammock Journal: Am J Respir Cell Mol Biol Date: 2015-01 Impact factor: 6.914
Authors: Meetha Medhora; Anuradha Dhanasekaran; Stephanie K Gruenloh; Laurel K Dunn; Michael Gabrilovich; John R Falck; David R Harder; Elizabeth R Jacobs; Phillip F Pratt Journal: Prostaglandins Other Lipid Mediat Date: 2006-07-25 Impact factor: 3.072
Authors: Emiko Ono; Stefanie Dutile; Shamsah Kazani; Michael E Wechsler; Jun Yang; Bruce D Hammock; David Nobuhiro Douda; Yacine Tabet; Rayan Khaddaj-Mallat; Marco Sirois; Chantal Sirois; Edmond Rizcallah; Eric Rousseau; Richard Martin; E Rand Sutherland; Mario Castro; Nizar N Jarjour; Elliot Israel; Bruce D Levy Journal: Am J Respir Crit Care Med Date: 2014-10-15 Impact factor: 21.405
Authors: Sumanta Kumar Goswami; Amelia Ann Rand; Debin Wan; Jun Yang; Bora Inceoglu; Melany Thomas; Christophe Morisseau; Guang-Yu Yang; Bruce D Hammock Journal: Life Sci Date: 2017-05-15 Impact factor: 5.037
Authors: Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan Journal: Prog Neurobiol Date: 2018-11-14 Impact factor: 11.685
Authors: Michael A Wells; Kimberly C Vendrov; Matthew L Edin; Brian C Ferslew; Weibin Zha; Bobbie K H Nguyen; Rachel J Church; Fred B Lih; Laura M DeGraff; Kim L R Brouwer; A Sidney Barritt; Darryl C Zeldin; Craig R Lee Journal: Prostaglandins Other Lipid Mediat Date: 2016-07-09 Impact factor: 3.072
Authors: Bora Inceoglu; Ahmed Bettaieb; Fawaz G Haj; Aldrin V Gomes; Bruce D Hammock Journal: Prostaglandins Other Lipid Mediat Date: 2017-08-25 Impact factor: 3.072
Authors: Sean D Kodani; Saavan Bhakta; Sung Hee Hwang; Svetlana Pakhomova; Marcia E Newcomer; Christophe Morisseau; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2018-01-04 Impact factor: 2.823